Person: SALMAN, ANDAÇ
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
SALMAN
First Name
ANDAÇ
Name
6 results
Search Results
Now showing 1 - 6 of 6
Publication Metadata only The Real-Life Effectiveness and Safety of Omalizumab Updosing in Patients With Chronic Spontaneous Urticaria(SAGE PUBLICATIONS INC, 2019) SALMAN, ANDAÇ; Salman, Andac; Comert, ElifBackground: Omalizumab is a third-line treatment for chronic spontaneous urticaria (CSU). Studies investigating the use of higher doses of omalizumab in patients unresponsive to regular doses are limited. Objectives: This study aims to investigate the effectiveness and safety of omalizumab 450 mg in CSU. Methods: A retrospective cohort study was conducted. The response to therapy was evaluated using the Urticaria Activity Score over 7 days (UAS7) and the Urticaria Control Test (UCT). Patients showing complete response (CR) (UAS7: 0-1) to omalizumab 300 mg (Group 1) and patients receiving at least 3 doses of omalizumab 450 mg (Group 2) between 2016 and 2018 were included. Results: A total of 72 patients (Group 1: 59; Group 2: 13) were included. In Group 2, the mean UAS7 score decreased from 18.6 to 5.1 and the mean UCT score increased from 8.6 to 12 after a mean 4.3 courses of 450 mg omalizumab treatment. Of the 13 patients in Group 2, 6 had CR and 3 had good disease control (UAS7: 2-6). The rate of patients with low baseline IgE levels (< 43 IU/mL) was significantly higher in Group 2. Conclusions: Higher doses of omalizumab are effective and safe in patients with CSU that is unresponsive to omalizumab 300 mg. Lower baseline total IgE levels might be used as a predictor of nonresponse to omalizumab and the need for higher doses.Publication Open Access Real-life data on the effectiveness and safety of omalizumab in monotherapy or combined for chronic spontaneous urticaria: a retrospective cohort study(TAYLOR & FRANCIS LTD, 2020-02-17) SALMAN, ANDAÇ; Salman, Andac; Ergun, Tulin; Maria Gimenez-Arnau, AnaBackground: The real-life data on the effectiveness and safety of omalizumab in chronic spontaneous urticaria (CSU) with validated methods are scarce. There is also a lack of information on the use of combination treatments. Methods: A retrospective cohort study was done to evaluate the effectiveness and safety of omalizumab in real-life conditions. The patients with CSU treated with omalizumab between 2015 and 2018 were included. The response to therapy was evaluated using urticaria activity score over 7 days (UAS7) and urticaria control test (UCT). Results: A total of 106 patients were included. A complete response (CR) (UAS7:0) and a well-controlled activity (WCA) (UAS7:1 to <6) were observed in 50 (47.2%) and 35 (33%) patients, respectively. The number of patients with an UCT score >= 12 was also significantly increased. Higher rates of CR/WCA were observed with omalizumab monotherapy compared to combination with antihistamines. The combination of dapsone, colchicine, and omalizumab provided additional benefit in a small group. Conclusion: Treatment with omalizumab provided a rapid and sustainable improvement in real-life settings. The use of omalizumab as monotherapy or combined with antihistamines does not show differences in the treatment response. The combination of omalizumab with immunomodulatory agents might be of benefit in selected cases.Publication Open Access Mesalazine-induced bullous fixed drug eruption(WILEY) SALMAN, ANDAÇ; Salman, Andac; Gencosmanoglu, Dilek Seckin; Alahdab, Yesim O.; Gimenez-Arnau, Ana M.Publication Metadata only The impact of omalizumab on quality of life and its predictors in patients with chronic spontaneous urticaria: Real-life data(WILEY, 2019) SALMAN, ANDAÇ; Salman, Andac; Demir, Gizem; Bekiroglu, NuralBackground Omalizumab is a third-line treatment for chronic spontaneous urticaria (CSU). However, the real-life data on the impact of omalizumab on CSU-related quality of life (QoL) remain scarce. Objectives To investigate the impact of omalizumab on QoL and its predictors in CSU. A retrospective cohort study was done. The response to therapy was evaluated using urticaria activity score over 7 days (UAS7) and urticaria control test (UCT); the impairment in QoL was assessed using dermatology life quality index (DLQI) and chronic urticaria quality of life questionnaire (CU-Q2oL). Results Forty-two patients were included. All scores improved from baseline to first month and remained stable at the third month of treatment (p < .001). The gender, age, and angioedema had no significant effect on QoL, but the complete responders (UAS7:0-1) had better improvement rates in all scores compared to others. The baseline UAS7, DLQI, and CU-Q2oL scores were lower at the baseline in complete responders (p = .0001). Conclusions A rapid and continual improvement in QoL was obtained with omalizumab treatment. A better UAS7, UCT, DLQI, and CU-Q2oL score at the baseline might be a predictor of a better response to omalizumab and more improvement in QoL.Publication Metadata only Prevalence of obesity in paediatric psoriasis and its impact on disease severity and progression(WILEY, 2017) SALMAN, ANDAÇ; Ergun, Tulin; Gencosmanoglu, Dilek Seckin; Karakoc-Aydiner, Elif; Salman, Andac; Tekin, Burak; Bulbul-Baskan, Emel; Alpsoy, Erkan; Cakiroglu, Aylin; Onsun, NahideBackground/Objectives: The current literature suggests there is a possible connection between paediatric psoriasis and obesity. However, there is a paucity of research on the influence of increased adiposity on the severity of paediatric psoriasis and disease progression. We aimed to compare the prevalence of being overweight or obese in paediatric psoriasis patients and controls and assess the potential impact of being overweight/obese on disease severity and progression of disease. Methods: This multicentre prospective case-control study included 289 psoriasis patients (aged < 18 years) treated and followed up by one of the four university hospitals in Turkey. The control group consisted of 151 consecutive age-matched and sex-matched children who lacked a personal or family history of psoriasis. The participants' characteristics, psoriasis-related parametres (e.g., initial subtype, psoriasis area and severity index, presence of psoriatic arthritis) and body mass index were determined. Results: The difference between the prevalence of being overweight/obese among psoriatics (28%) and the control group (19%) was significant (P = 0.024). Being overweight/obese had no significant impact on disease severity and unresponsiveness to topical treatment. Within a median follow-up time of 12 months, 23% of our patients with localised disease at disease onset progressed to generalised disease. The impact of being overweight/obese on disease progression was found to be non-significant; however, disease duration was found to have a significant impact on disease progression (P = 0.026). Conclusions: Although it is not associated with disease severity and course, increased bodyweight may be a health problem for psoriatic children.Publication Open Access Definition, aims, and implementation of GA(2)LEN/HAEi Angioedema Centers of Reference and Excellence(WILEY, 2020-08) SALMAN, ANDAÇ; Maurer, Marcus; Werner, Aberer; Agondi, Rosana; Al-Ahmad, Mona; Al-Nesf, Maryam Ali; Ansotegui, Ignacio; Arnaout, Rand; Arruda, Luisa Karla; Asero, Riccardo; Aygoeren-Puersue, Emel; Banerji, Aleena; Bauer, Andrea; Ben-Shoshan, Moshe; Berardi, Alejandro; Bernstein, Jonathan A.; Betschel, Stephen; Bindslev-Jensen, Carsten; Bizjak, Mojca; Boccon-Gibod, Isabelle; Bork, Konrad; Bouillet, Laurence; Boysen, Henrik Balle; Brodszki, Nicholas; Broesby-Olsen, Sigurd; Busse, Paula; Buttgereit, Thomas; Bygum, Anette; Caballero, Teresa; Campos, Regis A.; Cancian, Mauro; Cherrez-Ojeda, Ivan; Cohn, Danny M.; Costa, Celia; Craig, Timothy; Criado, Paulo Ricardo; Criado, Roberta F.; Csuka, Dorottya; Dissemond, Joachim; Du-Thanh, Aurelie; Ensina, Luis Felipe; Ertas, Ragip; Fabiani, Jose E.; Fantini, Claudio; Farkas, Henriette; Ferrucci, Silvia Mariel; Figueras-Nart, Ignasi; Fili, Natalia L.; Fomina, Daria; Fukunaga, Atsushi; Gelincik, Asli; Gimenez-Arnau, Ana; Godse, Kiran; Gompels, Mark; Goncalo, Margarida; Gotua, Maia; Gower, Richard; Grumach, Anete S.; Guidos-Fogelbach, Guillermo; Hide, Michihiro; Ilina, Natalia; Inomata, Naoko; Jakob, Thilo; Josviack, Dario O.; Kang, Hye-Ryun; Kaplan, Allen; Kasperska-Zajac, Alicja; Katelaris, Constance; Kessel, Aharon; Kleinheinz, Andreas; Kocaturk, Emek; Kosnik, Mitja; Krasowska, Dorota; Kulthanan, Kanokvalai; Kumaran, M. Sendhil; Larco Sousa, Jose Ignacio; Longhurst, Hilary J.; Lumry, William; MacGinnitie, Andrew; Magerl, Markus; Makris, Michael P.; Malbran, Alejandro; Marsland, Alexander; Martinez-Saguer, Inmaculada; Medina, Iris V.; Meshkova, Raisa; Metz, Martin; Nasr, Iman; Nicolay, Jan; Nishigori, Chikako; Ohsawa, Isao; Ozyurt, Kemal; Papadopoulos, Nikolaos G.; Parisi, Claudio A. S.; Peter, Jonathan Grant; Pfuetzner, Wolfgang; Popov, Todor; Prior, Nieves; Ramon, German D.; Reich, Adam; Reshef, Avner; Riedl, Marc A.; Ritchie, Bruce; Rockmann-Helmbach, Heike; Rudenko, Michael; Salman, Andac; Sanchez-Borges, Mario; Schmid-Grendelmeier, Peter; Serpa, Faradiba S.; Serra-Baldrich, Esther; Sheikh, Farrukh R.; Smith, William; Soria, Angele; Staubach, Petra; Steiner, Urs C.; Stobiecki, Marcin; Sussman, Gordon; Tagka, Anna; Thomsen, Simon Francis; Treudler, Regina; Valle, Solange; van Doorn, Martijn; Varga, Lilian; Vazquez, Daniel O.; Wagner, Nicola; Wang, Liangchun; Weber-Chrysochoou, Christina; Ye, Young-Min; Zalewska-Janowska, Anna; Zanichelli, Andrea; Zhao, Zuotao; Zhi, Yuxiang; Zuberbier, Torsten; Zwiener, Ricardo D.; Castaldo, Anthony